Logo image
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk
Journal article   Peer reviewed

More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk

Robert P McMahon, Stephan Arndt and Robert R Conley
Statistics in medicine, Vol.24(1), pp.11-21
01/15/2005
DOI: 10.1002/sim.1837
PMID: 15515151

View Online

Abstract

Common adverse effect measures in psychiatric trials are typically analysed with repeated measures ANOVA, despite having distributions which violate key assumptions of that method; moreover, some adverse effects may be concentrated in vulnerable subgroups of participants. For testing treatment differences in adverse effects, we propose use of Kendall's taub as a summary measure of within-participant trends in adverse events, in conjunction with a weighted modification of a rank test proposed by Conover and Salsburg. Data on extrapyramidal side effects from a controlled clinical trial conducted in persons with treatment resistant schizophrenia was used to compare the proposed analysis to repeated measures ANOVA using mixed models and alternate tests for treatment differences in taub trend scores.
Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Basal Ganglia Diseases - chemically induced Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Chlorpromazine - adverse effects Chlorpromazine - therapeutic use Computer Simulation Data Interpretation, Statistical Double-Blind Method Humans Psychiatry - methods Randomized Controlled Trials as Topic - methods Schizophrenia - drug therapy

Details

Metrics

1 Record Views
Logo image